

IV & Infusion Therapy Certificate

November 2020

Health Leadership & Learning Network



Dear Student/Participants,

Please find the York University copyright statement. This is an annual reminder to all students about the copyright policy of the University.

Access to and use of the course materials is restricted to students enrolled in the IV & Infusion Therapy Certificate course offered by Health Leadership & Learning Network. All materials for this course are provided with the permission of the rights holder, under the terms of a license or other agreement, or under the application of statutory exceptions of the Copyright Act. Copyright and all rights are maintained by the author(s) or by other copyright holder(s). Copying this material for distribution (e.g. uploading material to a commercial third-party website) can lead to a violation of Copyright law. Find out more about copyright here: www.yorku.ca/copyright

If you have any questions, please contact us here in HLLN at 416 736 2100 X22170 or hlln@yorku.ca. Thank you, Tania Xerri

Tania Xerri, Director, Health Leadership and Learning Network *A Leader in Health Continuing Professional Education* Faculty of Health York University 4700 Keele St. HNES 019, Toronto, ON M3J 1P3

Information, Privacy and Copyright | Office of the Counsel 1050 Kaneff Tower | York University | 4700 Keele St., Toronto ON M3J 1P3 Canada



KAREN LAFORET RN, MCISc, VA-BC[™], CVAA (C)

Karen Laforet is a Registered Nurse with a rich and diverse work history working in US, Germany and Canada. She is a nurse leader with over 30 years of healthcare experience in critical care, community care, industry and academia in US, Germany and Canada. She is currently the Director Clinical Services for Calea Homecare – a service provider for pharmacy & nursing in the Greater Toronto Area. She has proven skills in leadership, team building, clinical training and innovation, business development, marketing, and healthcare management.

Karen is currently a Board Member for the Canadian Vascular Access Association (CVAA), member of CVAA's best practice guideline development group, a committee member for College of Nurses of Ontario, member of International Guideline Development Group for Wound Infection, member of Wounds Canada Policy & Advocacy Committee, and current Past President of the Ontario Wound Care Interest Group (OntWIG). She is past president and founding Board for the Canadian Association of Critical Care Nurses, former board member of the International Association for Vascular Access, and member of RNAO Best Practice Guideline development team. She sits on the editorial review board for Infusion Nurse's Society Journal, Diabetic Foot Canada Journal, Journal of Vascular Access.







York University Faculty of Health

IV & Infusion Therapy Certificate

Table of Contents

Course Sche	dule	5
Week 1		6
Week 2		23
Week 3		41
Week 4		54



York University Faculty of Health

Course Title: IV and Infusion Therapy Certificate

Course Objectives

The Certificate in IV and Infusion Therapy will provide evidence-based education in vascular access, infusion therapy and patient safety, with an emphasis on high-risk settings such as home care, clinics and long-term care. The program is geared towards working health professionals who administer infusion therapy and provide care and maintenance for vascular access devices (VADs) in their organizations and those preparing for the Canadian national vascular access & infusion certification exam.

By the end of this course, you will be able to:

- Apply knowledge of anatomy and physiology to vascular access and infusion therapy.
- Examine the legal and quality assurance aspects related to infusion therapy practices to align with ethical and professional practice.
- Explain principles of non-touch aseptic technique specific to vascular access insertion and maintenance.
- Demonstrate understanding of pharmacy-therapeutics specific to infusion therapy in alternate care settings.
- Exhibit psychomotor critical thinking skills necessary for effective nursing management for patients receiving infusion therapy and total parenteral nutrition.
- Describe assessment and considerations for vascular access device selection.
- Identify the categories of devices available for vascular access.
- Gain confidence and skills, specific to the delivery of vascular access and infusion therapy such as venipuncture techniques, infection control techniques and basics of primary and secondary infusions.
- Apply evidence-based best practice that comply with standards set by provincial, national regulatory bodies to optimize patient safety outcomes.
- Increase awareness of resources to support practice and continuous learning opportunities.

Delivery method:

 Hybrid format (online and in-person) that includes five live webcasts and a skills laboratory workshop. Participants will have the opportunity to practice their IV insertion, venipuncture and infection control techniques in the skills laboratory

Course Resources:

- Canadian Vascular Access Association (CVAA)—resources on-line. Guidelines to be released 2018 <u>www.cvaa.info</u>
- Infusion Nurses' Society (INS)—standards of practice (2016), on-line resources www.ins1.org
- Association for Vascular Access (AVA)—on-line resources—<u>www.avainfo.org</u>
- National Home Infusion Association (NHIA)—on-line resources www.nhia.org
- CDC: guidelines, on-line learning modules & resources <u>www.cdc.gov</u>

Course Outline

Session	Торіс
1	Introduction to Infusion therapy
	Safe infusion practice
	Anatomy & Physiology of Skin
	Central Nervous System
2	Cardiovascular System
	 Vein anatomy & physiology
	Vascular access devices
	Site selection
3	Assessment and manage complications
4	 Administration of infusion therapy,
	Considerations re: blood products, parenteral nutrition & lipids
	Fluid & electrolyte balance
	Paediatric considerations: PVAD Site selection, fluid & electrolyte
	balance
	 Older adults: pharmacotherapeutics, VAD site selection, dressing
	selection, application & removal
5	Web-based workshop
	 Secondary Infusions, IV push medications and alternative infusion
	options
	Hypodermoclysis
	 Device care and management: site assessment
	 Dressing selection, application & removal
	VAD Securement and stabilization
6	Skills lab
	 PVAD insertion, securement and stabilization
	 CVAD dressing application, securement, stabilization and removal
	IVAD access
	 Troubleshooting (Case study format)
	Final exam

IV AND INFUSION THERAPY – COURSE SCHEDULE

Course Component	Time	Format
November 2, 2020	6:30 – 9:00 PM	Lecture 1 Group Session -Live on Zoom
November 9, 2020	6:30 – 9:00 PM	Lecture 2 Group Session -Live on Zoom
November 16, 2020	6:30 – 9:00 PM	Lecture 3 Group Session -Live on Zoom
November 23, 2020	6:30 – 9:00 PM	Lecture 4 Group Session -Live on Zoom
Cohort A	9-10 AM on Skills Lab Day 1	Group Session -Live on Zoom
December 3, 2020		Demonstration from Instructor
Cohort B		
December 10, 2020		
Cohort A	1.5 Hours – To be assigned at	Skills Lab – Intensive Semi-private sessions
December 3 & 7, 2020	the end of Lecture 4	Assigned timeslot in pairs – Live on Zoom
		Day 1 – 10:30 – 12:00 AM (Group 1)
Cohort B		Day 1 – 12:30 – 2:00 PM (Group 2)
December 10 & 14,		Day 1 – 2:30 – 4:00 PM (Group 3)
2020		Day 2 – 9 – 10:30 AM (Group 4)
		Day 2 – 11:00 – 12:30 PM (Group 5)
		Day 2 – 1:00 -2:30 PM (Group 6)
		Day 2 – 3 – 4:30 PM (Group 7)
Cohort A	10 AM – 4 PM	1-day Skills Lab In-Person on-campus
December 8, 2020		Practice
Cohort B		
December 15, 2020		















Objectives:

- By the conclusion of this session, participants will be able to:
- · Review rationale for infusion therapy
- Define common universal terms used for infusion therapy and vascular access
- · Discuss core safe infusion practices
- List six function of the integumentary system
- Identify risk to skin integrity for a person receiving IV therapy
- Compare the sympathetic and the parasympathetic nervous systems.

© Copyright Klaforet

Vascular Access gone wrong...





Core Practice Principles

- · Foundational elements to all practice:
- Infection Prevention and Control
- · Ethics
- Evidence-Informed Practice
- · Informed Consent
- · Hand Hygiene
- · Safe Handling and Disposal of Hazardous Materials & Sharps
- Product use (following Manufacturer's instructions)
- · Patient Education and Competency
- Documentation. •

Health Leadership & Learning Network

Infusion Therapy: History

- 1656 Sir Christopher Wren—used quill and bladder to inject dog with opium
- 1900 Gin Unitsuppler Wein–beste dyna and backet ei briger. Gog Min opunn 1834: Dr. James Blundell transfused women hemorrhaging post-partum 1900 Karel Landsleiner: 3 out of 4 blood groups 1925: Dextrose used as infusate 1940: disposable administration sets developed
- :
- 1950's: parenteral fluids introduced and used safely
- 1957: McGawa Labs introduced winged infusion needle (Butterfly)
- 1960: PICC lines introduced into ICUs
- 1960: PICC lines introduced in
 1963-65: first successful TPN
- 1964: First disposable IV catheter (Angiocath by Deseret)

- - © Copyright Klafore

Health Leadership & Learning Network

1964 First disposable cannula

8

Infusion Therapy

- · It is the most common invasive procedure in health care.
- 90% of all patients who experience healthcare will have an IV at some point in time (ISMP 2015, CDC 2012, SHN)

Health Leadership & Learning Network



© Copyright Klaforet

fluids, blood, and drugs directly into the vascular system: i.e. arteries, bone marrow and veins.

Health Leadership & Learning Network

Why Infusion Therapy?

- To administer fluids and medications
- To provide parenteral nutrition
- To provide avenue for dialysis/apheresis
- · To transfuse blood products
- · To provide avenue for hemodynamic monitoring
- To provide avenue for diagnostic testing



Healthcare professionals need to be proficient in the assessment, selection, insertion and care & maintenance of vascular access devices and the infusions/medications provided

> Health Leadership & Learning Network

CRITICAL for patient safety

Early recognition and prevention of complications.

Knowing anatomy, physiology and pathophysiology will minimize patient risk





Common Terms

- Infusion therapy: replaces IV therapy-it's more than 'pick and stick'
- VAD: Vascular access device (VAD) in place of IV catheter
 - $_{\odot}$ PVAD in place of PIV
 - $_{\odot}$ CVAD in place of central line or CVC or CIC
- Health Professional (HP or HCP) in place of nurse, doctor, phlebotomist...etc.
- DIVA: Difficult IV access

© Copyright Klaforet

Health Leadership & Learning Network

Infusion related clinical competencies

- Core content areas: Anatomy & Physiology
- · Fluids & Electrolytes
- Vascular Access—peripheral & central: assessment, selection, care & maintenance
 Infection control and safe infusion practice

- Complications
- Pharmacology (including chemotherapy)
- Pediatric Population Implications
- Geriatric Population Implications Transfusion Medicine
- Parenteral Nutrition

© Copyright Klaforet







12

















• Clinical implications for infusion therapy:

- Physical & functional characteristics
 - \circ Integumentatry
 - \circ Nervous
 - \circ Circulatory
 - $_{\odot}$ Vascular
 - $_{\odot}$ Skeletal

© Copyright Klaforet

• Know location of veins, arteries, nerves for vascular access



The skin of terrestrial animals is **essential** for their survival....the **principle role** of skin is to keep harmful agents out and water in. In order to accomplish this seemingly trivial task, nature has developed an elaborate structure, termed the **stratum corneum**, which provides to the skin its barrier function.

© Copyright Klaforet

Schaefer and Redelmeier

























17

Resident vs Transient Microbiota

- Resident
- Acquired rapidly during & after birth
- · Always present
- Unable to remove
- In health human internal tissues are free from microorganisms
 - Blood
 - BrainMuscle
 - o Musci

- Transient
- Live in or on the body for a period of time (hours, days, weeks, or months) then move on or die off
- Cannot live on d/t competition, elimination by body's defenses or chemical/physical changes in the body
- Able to remove through washing

Health Leadership & Learning Network

Symbiotic Relationship

- Mutualistic
 - \circ Both organisms benefit (e.g. E. Coli synthesizes Vit K & B)
- Commensalistic

$_{\odot}$ None with Bacteria

- \circ If on/in the skin either helping or harming
- Opportunistic
 - Pathogenic outside normal environment (e.g. E. Coli, Staph aureus



Threats to Skin Integrity

Moisture Associated Skin Damage (MASD)

General term for inflammation or skin erosion caused by prolonged exposure to a source of moisture such as urine, stool, sweat, wound drainage, saliva, or mucus



© Copyright Klaforet

Health Leadership & Learning Network

Medical Adhesive-related skin injury (MARSI):

© Copyright Klaforet

- Prevalent, underrecognised and preventable complication specifically related to skin damage caused by medical adhesive
- Can occur in any patient group or setting



























References

• Unless stated otherwise all images are from Karen's personal files

- Alexander, M., Corrigan, A., Gorski, L., Hankins, J., & Perucca, R. (Eds.). (2010). Infusion nursing: An evidence-based approach (3rd ed.). St. Louis, MO: Saunders/Elsevier. ٠
- MO: Saunders/Elsevier.
 CVAA Infusion therapy and vascular access guidelines. 2019.
 O'Grady, N.P., Alexander, M., Burns, L.A., Dellinger, E.P., Garland, J., Heard, S.O., & Healthcare Infection Control Practices Advisory Committee. (2011). Guidelines for the prevention of intravascular catheter-related infections. *American Journal of Infection Control*, 39(4 Supplement 1), S1-S34. Doi: 10.1016/j.ajic.2011.01.003.
 Weinstein, S., & Hagle, M. (2014). *Plumer's principles and practice of infusion therapy* (9th ed.). Philadelphia, PA: Wolters Kluwer Health, Lippincott Williams & Wilkins.

© Copyright Klaforet

Health Leadership & Learning Network

IV & Infusion Therapy Week 2

Karen Laforet MCISc, RN, CCHN (c), VA-BC[™], CVAA (c)

Objectives

- Identify key difference between artery and vein anatomy
- Name two veins commonly used for peripheral vascular access
- \bullet List components of the Cardiovascular System pertinent for Infusion therapy
- Outline the vascular access device process
- Differentiate peripheral devices and central devices
- Summarize the key components of vascular access device selection









An multiple venues pressure towards the hear. Yenueles (12-18 mmHg) to CVP (~fmmHg). Yenueles (12-18 mmHg) to CVP (~fmmHg). Stavity drains blood from head and netce. Muscle pumps Inbalation: thoracic cavity expands (\$ptopse), abdomina pressure \$ptopse), abdomina pressure \$ptopse). Blood flows faster with inhalation (COPD patients). Blood flows faster with inhalation (COPD patients). Copyet retimes





Tunica Adventitia the outer layer of the vessel • Connective tissue • Contains the arteries and veins supplying blood to vessel wall (Vasa vasorum) [may penetrate to the tunica media], lymph channels • Afferent and sympathetic nerves

















Peripheral vascular access devices are ubiquitous in healthcare and risk of harm is significant

Following evidence-based practices will help protect patients from infection.

۹Ds			
	Peripheral	Central	Special
	Over-the-Needle Short & Long length	Non-tunneled	Dialysis
	Butterfly	Tunneled	Apheresis
	Extended Dwell	Implanted	Umbilical
	Midline	PICC	Intraosseous
	Arterial		Hypodermoclysis

PVADS

- Approximately 75 % of all Intravenous Access devices inserted are peripheral
- Catheter, less than 3 inches (7.5 cm) in length
- Over-the-needle catheter is most common



PVAD

PVAD

• Tip terminates in a peripheral vein • Any catheter whose tip is not in the bottom 1/3 of the superior vena cava (or is considered a peripheral VAD

Example- Tip position in the Subclavian vein



PVAD: Midline Catheters

PVAD's with the tip terminating in the Basilic, cephalic or brachial vein distal to the shoulder—level with axilla

- Single or double lumen
 1.9 Fr 5 Fr (adults); 22-24 g for pediatric catheters
- Polyurethane or silicone material

Initiated above or below the Antecubital Fossa in one of the following • Basilic

- Basilic
 Cephalic
- Median Cephalic
- Brachial Veins









CVAD Tip Location

- Ensure optimal tip location for CVADs [IC]
 - In distal superior vena cava (SVC) or cavoatrial junction (CAJ); if using CXR, measure from carina, trachea-bronchial angle, or thoracic vertebral bodies [IB]
 - Femoral VAD should have tip location within the inferior vena cava and above the level of the diaphragm.



Non Tunneled Catheters

- Recommended for short-term access to the central circulation in critical situations, or when peripheral access is inadequate or inappropriate.
- Used mainly for ICU/CCU patients. Not safe for alternate care settings
- Percutaneous insertion of catheter into the IJ, subclavian or femoral site
- Associated with high risk of CRI d/t skin exit pint of catheter in close proximal to the entry point of vein used
- Available in single, double, triple, quad or 5 lumenGenerally open-ended.







Implanted Devices (aka "Port")

- An implanted reservoir generally placed in the chest or arm, attached to a catheter with tip position in the central vasculature.
- Infusate is delivered to the reservoir via an external non-coring needle and extension tubing





Implanted Devices

- Requires a minor surgical procedure for placement and removal.
- When not in use, requires less maintenance than other VADs.
- Medication delivery requires injection through skin using a non-coring needle
- Intended for long term therapy up to 5 years
- Q 6 -12 week flush with 0.9%NaCl for maintenance (Heparin may be ordered)
- Implanted devices with or without valve



Central Tunneled Catheters

- Intended for long term therapy > 30 days
- Valved (e.g. Groshong) Catheters- saline only flush
- Open ended (e.g. Hickman) catheter • Flush with 10 cc Saline & locked with 100unit per mL Heparin
 - Lock with positive pressure technique using clamp

Valved vs Non-valved catheters

- Non-valved VAD: open-ended tip; lumen hub has clamps on external portion of catheter to stop backflow
- For IVAD: refers to device not having an integrated valve
- Valved VAD: integrated valve
 - Valve located at catheter tip (distal end) or in the catheter hub (proximal end)
 Valve opens with infusion or flushing and when pressure is exerted for aspiration or blood sampling
 - Valve is neutral or remains closed when no pressure is applied
 - Prevents blood coming into the catheter





Hemodialysis VAD

- Tunneled or implanted VAD; AV fistula, or insertion of arteriovenous graft:
 All considered surgical procedures
- Administering meds, solutions through any hemodialysis device requires specific MD order
- Can a nurse remove one of these devices? Yes: if validated competency
- Venipuncture is not to be performed on the extremity containing AV fistula or graft
- Vein preservation KEY for patients who are likely to need vascular access for hemodialysis
 Any access is considered sterile: sterile gloves and mask required
- Can one use PI ointment or Polysporin at exit site? Yes: only if ointment doesn't interact with catheter material as per manufacturer's IFU. ONLY CVAD where ointment is used

Apheresis & Ultrafiltration

- Large bore central catheter, percutaneously or surgically placed to maintain high flow rates and accommodate large bld volumes. Apheresis: removal of blood plasma from the body by withdrawal of blood
 Separates into plasma and cells

- Cells reintroduced
- Used to remove antibodies in treating autoimmune diseases

- Tip of catheter resides at junction of SVC and R atrium
 Ultrafiltration: removes excess salt and water in patients in fld overload (e.g. CHF)


Umbilical Catheter

- Arterial or venous access for newborns
 - Arterial with vehicus access for hewdorms
 Arterial umbilical catheter trip is located in the descending aorta above the level of diaphragm and below the L subclavian artery
 Venous umbilical catheter trip: located in inferior vena cava above the level of diaphragm
 Removal: performed aseptically, slowly over several minutes; manual compression with sterile gauze until hemostasis
 Monitor site V12 her theo doily.

 - Monitor site X12 hrs then daily
 Complications: bleeding/hemorrhage, air embolism, infection, thrombosis, vascular perforation, peripheral vascular constriction.

Interosseous

- Inject directly into the marrow of a bone.
- Provides fluids and medication when intravenous access is not available or not feasible
- Emergency access:
- i.e. codes, in the field, pediatrics
- SOP: pediatrics: after 2 attempts use I.O. access and replace within 24 – 48 hours



VAD Selection (CVAA, 2019)

- Determine the appropriate type of VAD:
- a) Use device with minimum number of lumens
 b) Always select the smallest gauge catheter that will accommodate the prescribed therapy
- c) Consider use of a 22-gauge PVAD for most infusion therapies.
- d) Consider using longer length PVAD for insertion with ultrasound

VAD Access Site Preparation

College of Nurses Standards

• MD order required to place a device

• Nurse shall be competent in:

- Insertion technique
- Infection prevention measures
- Identifying potential complications
- Implementing nursing interventions

Primary Goal

One patient One stick One device



VAD Planning (CVAA 2019)

- 1. Use a systematic process to develop a patient-centric vascular access plan prior to or at onset of therapy that optimizes vessel preservation and guides device selection.
- 2. 2. Ensure VAD planning is an ongoing process throughout treatment.
- 3. 3. Determine: is vascular access is necessary or if an alternate route is appropriate (e.g., oral, sublingual, inhaled, nasal, transdermal, topical, subcutaneous)

4. **Select** the device that is the least invasive for the duration and type of therapy and promotes vessel preservation.

Principles of site selection

- Catheter/Vein Ratio
- Hemodilation and hemodilution (Dilution of infusate)
- Vessel preservation
- Location
- When would you use the hand vs the forearm? (there are exceptions)
- A TRUE emergency (person is to die in the next 90 sec)
- Just because the vein is large doesn't mean you put in a large cannula

"If you want an IV to fail, put it in the elbow or the hand" $_{\mbox{(1 LeDonne)}}$

Device Selection (CVAA 2019)

Determine the appropriate type of VAD:

- Always select the smallest gauge catheter that will accommodate the prescribed therapy
- Consider use of a 22-gauge PVAD for most infusion therapies.
- Consider using longer length PVAD for insertion with ultrasound

Determine vascular access needs according to:

- a) Intended frequency and duration of therapy b) Prescribed therapy (e.g., osmolarity, pH, vesicant, and irritant properties)
- c) History of vascular access and comorbidities (e.g., renal status)
- d) Age and developmental stage
- e) Anatomy
- f) Activities
- g) Skin integrity
- h) Patient's preferences and lifestyle
- i) Available resources for VAD care and maintenance.Identify risks and benefits associated with each type of VAD
- Determine the minimum number of lumens required for the plan of care
- Determine if a VAD designed with power injection capabilities is needed

(CVAA 2019)

pH Scale

- Measures concentration of hydrogen ions (H+) in a solution.
- 0 to 6 being acidic,
- 7 neutral
- 8 to14 being alkaline (base)
- What is critical to understand is that a small change in pH results in a large change in H+ ion concentration.

pH - Blood pH = 7.35 - 7.45

- pH of 5 9 minimizes disruption of venous endothelium
- Medications & IV fluids with a pH of 5-9 can be safely administered via peripheral IV





Acid pH Scale for common Medications

Acid

- Stomach Acid pH 1
- Lemon Juice pH 2
- Vinegar pH 3

Neutral

• Tap Water pH 7

Ciproflaxin pH **3.3-4.6** Tobramycin pH **3-6.5**

Vancomycin pH 2.4

Drug/Fluid

Erythromycin pH 6.5-7.7 Ceftriaxone pH: 6.5 - 7

Type of VAD	Selection Recommendations	CVAA Guidelines 2019
PVAD	Accessible peripheral veins in the upper extremit Short term duration of therapy (e.g., < 7 days) [Osmolarity of continuous solutions and/or me (e.g., < 7 days) [2 days) (exception: immunoglobulin) [ICVA Extremes of pH, use with caution [ICVAA] Intermittent vesicants/irritants. Ongoing cli vesicants/irritants [ICVAA] Monitor for win depletion and repeated failed j	y for duration of therapy (INS, 2016; RCN, 2016) [IC ICVAA] (dications < 600 Osm/L for short-term duration (e.g. A] nical assessment needed for sequential or cyclica peripheral access [ICVAA]
Midlines	Accessible peripheral vein in the upper extrem 2016) [IC] Duration of therapy < 4 weeks (INS, 2016, RC Osmolarity of continuous solutions and/or me <7 days) [ICVAA] Extremes of pH ₁ use with caution [ICVAA]	ity above antecubital fossa (ACF) (INS, 2016 ₁ RCN N, 2016) [IB] dications < 900 Osm/L for short-term duration (e.g
CVAD (non- tunneled, PICC, tunneled, implanted vascular access device (IVAD))	Suitable peripheral access is unavailable (INS, 2 Consider implanted or tunneled CVAD for long Osmolarity of solutions and/or medications > Continuous vesicant infusion > 60 minutes [IC Consider long-term intermittent vesicant infusi Consider CVAD for irritati infusions > 60 min	8016) [IC] gterm therapy (epic3, 2014; INS, 2016) [IIC] 900m/L (e.g., parenteral nutrition) (INS, 2016) [IC] VAA] on (INS, 2016) [IC] utes or oneoping intermittent infusion [IICVAA]



D0 Not Use:

i. Areas of flexion (e.g., wrist, ACF), except in trauma or emergency situation (to avoid nerve damage and depletion of antecubital veins)

- ii. Chest wall, digits, or breast iii. Lower legs, except in non-walking children

iv. Insertion areas that are painful on palpation or with veins that are obviously compromised (e.g., thrombosis, redness, cording, bruising, infiltration, phlebitis, engorgement)

v. Extremity with arteriovenous (AV) fistula/graft site

vi. Affected extremity after extravasation for subsequent VAD insertion until symptoms are resolved (RCN, 2016).

1. Cephalic

- 2. Median Cubital Vein
- 3. Accessory Cephalic Vein
- 4. Basilic Vein
- 5. Cephalic Vein
- 6. Median Ante Brachial Vein



Health Leadership & Learning Network

IV & Infusion Therapy Week 3

Karen Laforet MCISc, RN, CCHN (c), VA-BC[™], CVAA (c)

Objectives

- \bullet List potential complications that may occur when a VAD is in situ (PVAD or CVAD)
- Identify prevention strategies to reduce risk of complications
- Discuss the need for regularly or routine VAD observation
- Differentiate infiltration from extravasation
- Explain the role fibrin places in VAD occlusion
- Describe steps to assess and manage complications

Case Study



- 89 yrs old male admitted from ER to Orthopedic Unit with a fractured L hip following a fall.
- #20 gauge IV catheter—inserted into L forearm (L arm edematous--etiology unknown)
- Film dressing with border intact. Small amount of sanguineous drainage noted under dressing
- Several pieces of tape secure the IV tubing on underside of arm
- Skin tear post tape removal

VAD Assessment O.P.A.L. 2018

- O: Observe fluid container, infusion system, insertion site
- P: Palpate the insertion site for changes in temperature, erythema, tenderness or firmness along the vein
- A: Aspirate for free-flowing blood return that looks like whole blood (robust blood flow)
- L: Listen to the patient concerns and symptoms.









Possible VAD complications

- Phlebitis
- Infiltration
- Extravasation
- Embolism
- Blood vessel damage
- Thrombosis
- Nerve injury
- Infection
- Catheter migration

Phlebitis

- Definition: inflammation of one or all three layers of the vein wall.
- Causes:
 Mechanical
 Chemical
 Bacterial
- Bacterial
 Signs and symptoms
 Erythema
 Swelling
 Pain
 Tenderness
 Induration
 Warmth
 Cording
 Red streak

	Phlebitis Scale
Grade	Clinical Criteria
0	No symptoms
1	Erythema at access site with or without pain
2	Pain at access site with erythema and/or edema
3	Pain at access site with erythema; Streak formation; Palpable venous cord
4	Pain at access site with erythema; Streak formation; Palpable venous cord >1 inch in length; Purulent drainage



Prevention

- Medication
- Venous access
- Securement/Movement
- Choosing appropriate devices
- Monitoring VADs closely

Intervention

Stop infusion at the first sign of phlebitis
Determine the etiology of the phlebitis

- Discontinue PIV catheter and restart at a new site or consider alternate mode of delivery
- Apply warm packs
- If discontinuing treatment, ensure patient is educated on after-care

Infiltration

 Definition: Inadvertent administration of IV fluids (<u>non-vesicant</u>) into the surrounding tissue



Catheter placed in area of flexionDislodgement of catheter



Infiltration Scale⁵

- Grade Clinical Criteria
- 0 No Symptoms
- 1 Skin blanched, edema <1 inch, cool to touch, with or without pain
- 2 Skin blanched, edema >6 inches, cool to touch, with or without pain
- 3 Skin blanched/translucent; gross edema>6 inches; cold to touch; mild to moderate pain; possible numbness
- 4 Skin blanched/translucent; skin tight, leaking, discoloured, bruised, swollen; gross edema > 6inches, deep pitting tissue edema, circulatory impairment, moderate to severe pain; infiltration of any amount of blood product, irritant or vesicant

Prevention & Management

- Selection of appropriate VAD –size & catheter
- Technique
- Securement
- Monitoring
- Stop infusion and remove PVAD
- Warm compress



Extravasation

- Definition: Inadvertent administration of a <u>vesicant</u> medication or solution into the surrounding tissues.
- Causes:
 - Infusion of hyperosmolar or infusate that is acidic, alkaline, vasoconstrictive, or cytotoxic
 Inadequate securement of VAD
 Traumatic insertion

 - Multiple venipuncture attempts
 - Small or frail veinsPIV site in area of flexion

 - Use of an infusion pump or power injectionPresence of a fibrin sheath
 - Dislodged or non-coring needle for ports.



Prevention

- Recognizing the type of medication and its effect as an irritant Example: Acyclovir (pH 10.5-11.6)
- Instruct patient to inform staff of pain and burning at insertion site
- Recognize institutional policies and procedures for administering vesicant medication
- Avoid using the dorsal surface of the hand and areas of flexion where tendon and nerve damage is likely to occur
- Give vesicants last when multiple drugs are ordered

Interventions

- Elevate affected extremity
- Contact physician
- Local thermal application (Cold or heat)
- Documentation
- Antidotes



NON-VESICANT Infusions PVAD¹

Acute care continuous infusions Every 4 hours, alert/oriented Every 1 - 2 hours for sedated patients, who are cognitively or sensory impaired or critically ill.

Alternate care settings Once a shift or visit Instruct patient/caregiver how to assess PVAD every 4 hours while awake and to report any changes immediately

Electronic Infusion Devices



VESICANT Infusions PVAD¹

- Every 5 10 min—any solution or medication with ↑ clinical risk ⁽⁶⁾
- Every ≤30 min for nonchemotherapy vesicants
- Every 2 5 mL confirming blood return for IV push chemotherapy agents

Vesicants

Neonates & Paediatrics¹

Every 1 - 2 hours or more frequent observation





Equipment contamination 13, 14

- Touch points include:
 - Catheter hub,
 - Injection ports
 - Administration set
 - Medication/infusi on administration





Idle catheters

- Catheters are a nidus for infection due to fibrin build-up
 Increased risk of
- Increased risk of contamination each time the device is accessed:
- Flushing frequency ask why so often?
- Contamination at hub or with flush syringe.





Patency, Flushing & Locking



- Flush VAD and confirm patency at established intervals: IVAD (non-accessed/not in use): no more frequently than monthly: consider extending frequency to three months
- •
- Lock all VADs with the sterile preservative-free 0.9% sodium chloride flush using the appropriate technique to maintain VAD patency. Aspirate all alternative lock solutions prior to use of the VAD or according to MRP/manufacturer's instructions for use •
- Exception: low-dose heparin (e.g., 10 or 100 units/mL) may be flushed through
 - If unable to aspirate, alternative lock solutions may have to be flushed through (except high-dose heparin, e.g., if therapeutic dose must be flushed through, MRP should be notified).

Aseptic technique 14, 16

- Asepsis is defined as a process for keeping away disease-producing organisms in sufficient quantity to cause infection
- Whether the procedure is "simple" or complex, the goal for healthcare professionals is to prevent the transfer of pathogens
- Aseptic non-touch technique (ANTT[®])

Catheter Related Blood Stream Infection (CRBSI)

Interventions

- · Assess for signs and symptoms of CRBSI
- · Examine the patient and carefully rule out other sources of infection
- Cultures · Consider time-to-positivity blood cultures
 - When a sample for blood culture is drawn, the needless connector should be changed prior
 - Draw out blood cultures prior to the initiation of antimicrobial therapy
 - · Antimicrobial therapy is based on identified or presumed microorganism

Signs and Symptoms of CVAD Occlusion

Upon Infusion or Flushing Resistance

- Sluggish flowInability to infuse fluids
- Frequent occlusion alarms on infusion pump
- Infiltration or extravasation or swelling or leaking at the insertion site.

• Upon aspiration of blood

- Inability to withdraw blood
- Sluggish blood return







Medical Adhesive-related Skin Injury (MARSI) ^{2,3,6}

 An occurrence in which erythema and/or other manifestations of cutaneous abnormality (including, but not limited to, vesicle, bulla, erosion, or tear) persists 30 minutes or more after removal of the adhesive."²

Moisture Associated Skin Damage (MASD)⁷

- Describes the spectrum of damage that occurs in response to the prolonged exposure of a patient's skin to perspiration, urine, feces, wound exudate etc.
- VAD-associated MASD is related to insertion site leakage or increased moisture due to skin damage



Tension Injury

Allergic Contact Dermatitis



Protect skin 2, 3, 7, 8

- Antiseptics and adhesives are chemicals that may irritate the skin
- Skin MUST be clean and dry before applying any product
- For patients at-risk of skin breakdown, or for patients receiving longterm therapy, apply skin protectant prophylactically
- Alcohol-free product to reduce xerosis
- VAD application requires sterile product
- Avoid water soluble products if exudate or denuded skin
- Products must be completely dry before applying the dressing

Air Embolism

Definition: when air enters the vascular system leading to complications

- Causes:
 Catheter fracture
 Disconnection of V sets
 Deep inspiration during catheter removal/access device change Deep inspiration during cath
 Signs and symptoms
 Hypotansion
 Pallor
 Palpitations and arrhythmias
 Chest and shoulder pain
 LOC
- ECC
 Prevention
 All air purged from syringes, administration sets, needless connectors
 Clamp open-ended catheters
- Management
 Position the patient in left lateral Trendelenburg
 Administer Oxygen

Health Leadership & Learning Network

IV & Infusion Therapy Week 4

Karen Laforet MCISc, RN, CCHN (c), VA-BC[™], CVAA (c)

Objectives

- Differentiate fluid balance in adult, older adult, paediatric populations
- Describe infusion therapy and name three types seen in your care setting
- Identify a critical safety step when infusing blood or blood products
- Explain the difference between primary and secondary infusion and safety considerations for both
- Name five ways pediatric patients differ from adults specific to vascular access insertion
- Discuss medication safety considerations for older adults

Agenda

- Infusion solutions
- Paediatric Considerations
- Older Adults
- Aseptic Technique
- Infusion Complications
- Transfusion
- TPN
- Documentation guidelines

Health Leadership & Learning Network





Definition of IV infusion

- Regarded as an amount of fluid in excess of 100mL designated for parenteral infusion because the volume must be administered over a long period of time
- Solution is defined by the USP as a liquid preparation that contains one or more soluble chemical substances usually dissolved in water.
- Solutions are not intended for admin by infusion or injection

Characteristics and Types of IV Fluids

- Fits into three main categories
- Isotonic
- Hypertonic
- Hypotonic

	Hypotonic	Y Isotonic	Y Hypertonic
Description	 A solution which has less solutes than another solution. 	A solution which has the same amount of solutes with another solution.	A solution which has more solutes than another solution.
Effect on animal cell	Water enters the cell. Cell expands and may finally bursts (Condition known as haemolysis if involves red bood cells). Water	Water molecules move in and out of the cell at same rate. Water	Water moves out of the cell. Cell shrinks (crenation).
Effect on plant cell	Water enters the cell. Cell becomes very turgid.	Water moves in and out of the cell at the same rate. Cell is turgid (normal).	Water moves out of cell. Cell becomes flaccid (plasmolysis). Veter

Isotonic Solutions

- Examples:
- Lactated Ringers (275 mOsm/L
- 0.9%NaCl
- 2.5% dextrose/0.45% sodium chloride
- 5% dextrose and water
- Normosol[®] 3
- . Plasmalyte® A
- . Plasmalyte® R
- . Isolyte[®] • E · Ringer's

- ECF fluid replacement--dehydration
- Treating metabolic acidosis
- Sodium depletion
- Initiating and terminating blood infusions Closely monitor for fluid overload
- Liver converts lactate to HCO3 so do not infuse in someone with pH>7.5
- 5%DW after admin, dextrose is quickly metabolized leaving only water (hypotonic). Monitor for fluid overload

Hypertonic Solutions

- Osmolarity is >300 mOsm/L (higher than solute concentration in serum)
- Exerts more osmotic pressure than ECF.
- When used fluid is pulled from the cells and interstitial compartment into the blood vessel.
- E.g. Blood cells placed in a hypertonic solution will lose water to the solution (to balance solute concentration) therefore cells will shrink.
- Patients receiving hypertonic solutions need to be monitored closely for fluid overload.
- Used post-op to \downarrow risk of edema, stabilize BP, regulate urine output

- See post-op to 4 his of eventa, stabilize br, regulate on
 Examples:

 3 5% NaCl
 10 20% Dextrose in Water
 5% Dextrose in Lactated Ringers; 5% Dextrose in 0.45% NaCl
 10% Dextrose and 0.45% MaCl
 5% NaBicarb injection; 10 15% Mannitol

Hypertonic Solutions

- Administer with great caution to prevent pulmonary edema
- Infuse hypertonic NaCl solutions slowly—e.g 200 mL over a minimum of 4 hours
- Careful to prevent infiltration and trauma to the tissues
- Should only be used in critical situations (Na: <110 mEq/L) with neurological symptoms
- Administer in controlled setting like ICUOnly small volumes needed for
- correction
- Use pump to control infusion

Hypotonic Solutions

- Osmolarity < 280 mOsm/L (lower concentration than serum)
- \bullet Exert less osmotic pressure that fluid in the ECF therefore water is drawn from the ECF.
- Fluid shifts out of blood vessels into the cells and interstitial spaces
- Blood cells placed in a hypotonic solution will draw the solution into the cells (causing swelling and bursting).

Hypotonic Solutions

Examples:

- 0.45%NaCl (154 mOsm/L)
- 0.33%NaCl (103 mOsm/L)
- 2.5%DW (126 mOsm/L)
- Administer cautiously
- Causes a fluid shift from the intravascular (Bld vessel) into the ICF
- Can cause cardiovascular collapse from IVF depletion and ↑ fluid in brain cells
- Do not give to patients at risk of 3rd spacing: burns, trauma, low serum protein, liver disease or malnutrition

Paediatrics





Physical and developmental considerations

- Body circumference changes 3X increase in length and approx. 20-fold increase in weight between birth and adolescence
- Stress level and basal metabolic rates are exceedingly higher than adults

Common reasons for IV therapy

- Maintenance of fld therapy:
- Younger the child greater risk of fluid & electrolyte imbalance
- Antibiotic therapy
 - Most common reason in Paeds is sepsis
 Choice of device based on length of treatment and vein availability
- Medication therapy
- Anticancer drugs
- Nutritional support
- Transfusion therapy

Anatomy and Physiology

- 1. Vessel size smaller- locations the same
- 2. Circulating blood volume-greater per unit of body wt
- Neonate: 85-90 mg/ml
- Infant Child: 75-80 mg/ml
- Child : 70-75 mg/ml
- Adolescent: 65-70 mg/ml
- 3. Fluid and electrolyte metabolism-
- ↑ amount free water in extracellular space - $\hfill \wedge$ Na and Cl ----- \downarrow K, Mg and phosphate

Anatomy Physiology (2)

4. Thermoregulation

- Thin subcutaneous leads to ↑ loss of heat- cold stress Loss of heat → hypothermia → ↑oxygen and caloric requirement
- Keeping baby warm is a priority

5. Renal function

- May have difficulty dealing with fluid /electrolyte balance
 Watch for fluid overload d/t hyperosmolarity; happens very quickly



Special Considerations

- Neonates: Birth to 4 wks. Can loose fluids quickly
- Infants: 1 to 12 months. Growing quickly
- Toddlers: 12-36 months. Aware of surroundings
- Early childhood: 36 mths-6 yrs. Understands, questions reacts
- School age : 6-12 yrs. growth spurts
- Adolescent : 11-18 years: hormones, emotional development

Considerations

- Neonates and Infants : Involves family in the process Take time to explain using simple terminologies

 - Scalp IVs can be distressing to parents
 People can think medication is going to the brain
- Toddlers and up: Being in the correct environment
 - Involve parents
 - Room is their safe area consider using designated treatment area
 Consider sedation if child is too restless or stressed
 - Addressing their curiosity for a better experience, doll with IV in
 Requires patience and creativity

 - · For prolonged therapy consider PICC lines to reduce stress of venipunctures

Considerations (2)

- Detailed attention needed in dosage calculations/infusion rates
 Smaller vessels require slower infusion to prevent complications like extravasation or infiltration
 Check infusion site frequently
 Smaller catheters require more frequent flushing
 Monitor output
- Body height and weight very important in calculation of dosages

- Choose the correct equipment
 Correct gauge and sized needles
 Chichexidine is not considered appropriate for use in children under 2 months
 Immobilizing the limb
 Topical anesthetic
 Warm packs

Types of Vascular Access

- PIV: short term and easily dislodged
 - Over the needle catheters 27-19 gauge < 2"
 Midlines

Intraosseous

If 2 unsuccessful attempts or circulatory collapse
Must be changed within 24 – 48 hrs.

	Advantages	Disadvantages	Veins
Non-Tunnelled CVC	For short term emergency Tx in critical care.	High risk of infection if access is proximal to	Internal Jugular
	No needle sticks involved. Lower rates of	diaper area. May be difficult to access in	Internal Subclavian
	infections in Paeds than adults	infants due to significant superior arch of the subclavian vein	Femoral veins
Tunnelled CVC	Lumens larger than PICCS=more fluid	At risk of accidental removal, if child is very	Tunneled via internal jugular veins an
	volume. Less risk of infection than Non- tunnelled CVC. Easily accessed for care by patient and family	active. Insertion procedure is invasive and requires anesthesia	subclavian, exits in the chest
Peripherally	No needle stick involved in insertion. Less	Higher infection rate in neonates than in	Inserted in the basilic, internal jugular
Implanted Central Catheter	invasive, more economical. After care is easier	children, contraindicated in patients with chronic renal failure	lower extremities (saphenous or popliteal), scalp vein
Implanted Ports	Surgically placed and tunnelled. Lowest risk	Painful during accessing. Ports may be	Internal and external jugular as well a
	of infection compared to other CVCs. No external connection to pull Allows for swimming.	displaced with vigorous activities. Surgically removed	cephalic veins
Hemodialysis	Catheters are large-bore and double lumen	2single lumen catheters Recommended over	Tunneled via jugular vein, ends in the
Catheter	for haemodialysis, peritoneal dialysis and renal transplant patients	1 double lumen catheter for improved performance	atrium. Femoral vein feasible as well





Sites	Pros	Cons	Precautions
Scalp	Veins are: Readily visible, easy to access, no valves. Commonly used in infants and toddlers. Not easily tampered with	Infusion can infiltrate easily May lead to distorted appearance of Infants heads with infiltration Cannula may not be easy to secure	Aim needle downward towards venous return flow. Be aware of family's cultural orientation towards hair shaving and appearance
Foot	More visible in chubby infants, veins readily dilate, hands remain free. Beneficial with children presenting with neuropathy eg spina bifida	Prevents walking High risk of phlebitis Limited sizes of cannula	Though child may not be walking, but may kick often
Upper Extremities	Easily accessible and palpable in older children, use of larger catheters sizes enabled, access to larger veins for increased haem dilution	Increased nerve endings hence more painful Challenging access in chubby children	Childs activities requiring use of hands may be restricted



Site	Pros	Cons	Precautions
Femoral	Bigger veins Does not have too much bacterial growth	Difficult to maintain due to increased activity of lower limbs in children. Needs limb immobilization	Restraining required
Umbilical	Accessible in neonates and 1 week old in critical situations	Need special training Heavily colonized area	Used only in emergency situations
Intraosseous	Provides immediate access	Need special training	Used only in emergency situations



Complications

- Occlusion
- Thrombosis- congenital heart disease, oncology and GI issues
- Malposition: can lead to endothelial wall injury
- Air embolism
- CLABSI- more common in immunocompromised children
- DVT
- Phlebitis occurs usually after age 10

Risks of infusion therapy in Children

• Acidosis related to poor thermoregulation

Dehydration or over-hydration
Immature liver results in electrolyte imbalance

Maintenance

- Keep access sites warm
- Keep infants warm
- Avoid use of kling/any wrap over sites for quick and frequent visual assessment
- Use appropriate stabilizers to prevent catheter dislodgement (arm pads, IV house)

Use asepsis for prevention of any and all infections!!!! NOT just for kiddies!







Factors Affecting Skin Characteristics over time

- · Increased dryness and wrinkles
- Decreased number of sweat glands, subcutaneous fat & vascularity
- Decreased epidermal turnover
- Vitamin D production is decreased
- · Elastin fibres calcify
- Dec vascular network hair follicles and glands
- Shorter capillary loops
- Dec nerve endings
- Decreased skin tugor (lost of mucopolysaccharides—sebum prod)
 Decreased sweat glands and sweat production
 Dec melanocytes = ↓ protection from UV
 Dec mast cells = ↓ histamine release (delayed reaction response)

Where's the water?

- Adult body is approximately 60% water
- Older adults are closer to 40 -50% water
- Most of body's water is intracellular—especially muscle Aging ↓ muscle mass = bodies contain < water

Total Body Weight (TBW) 60% water

ICF = 40% ECF = 20% Body Body weight weight

Dehydration Problem for Older Adults

• Older adults have: • Less muscle = less water

• ↓ thirst

Chronic dehydration

• Dehydration is difficult To correct Chronic dehydration = lose

symptoms that tell you are...

Need to identify impending dehydration: • Lab tests: BUN: Creatinine

- ratio >25 Na (↑); Glucose (↑), Bicarb (↓) Dry mucous membranes—
- mouth & nose Tongue furrows Dry axilla • •
- . Sunken eyes

• Poor skin turgor

What's the risk?

- Less TBW means less drugs are distributed in water (water soluble meds) therefore lower dose is needed in an older adult
- Less water means ↑ risk of dose toxicity



Specific considerations: Vein selection

- Thin skin and loss of subcutaneous fat \rightarrow mechanical inflammation and infiltration
- If possible select sites with sufficient tissue and skeletal support



Things to remember

- Older adults may not be aware of his or her surroundings; slower to adapt to environmental changes
- They might get tangled, tripped or fall
- Make sure the tubing is not dangling or dragging on the floor



VAD insertion for Older Adults

- Pre-hydration is often necessary before insertion
 - This is important specially with significant loss of fluid or induction of high risk
 medications that have the potential for irritation

 - This will help prevent intravascular depletion
 - Insertion of the larger VAD will be much easier.

Vein selection



- Assess entire surface of both arms
- Skin condition
- When possible, sites should not hamper older adult performance of ADL
- Site should have sufficient tissue and skeletal support
- Distal sites (first) to preserve future access sites
- Avoid previously used insertion sites; bruised areas
- No larger than 22ga. 24 Ga preferred

Things to remember

- Skin is fragile and delicate → too vigorous scrubbing or pulling action may damage surface skin tissue
- \bullet Older skin has lost some natural moisture \rightarrow excessive use of alcohol may add skin dryness and cracking
- Allow the antiseptic to dry completed (at least 30 to 60 seconds)
- Shaving not recommended \rightarrow remove hair by clipping



Things to remember

- Amount of tape applied to the skin should be minimized in patient with delicate skin
- Skin barrier can be use to protect skin from the effect of adhesive/drying nature of the antiseptic/ repetitive tape removal and dressing changes

Remember:

Hard and stiff edges of the IV devices can cause older skin to become irritated, sore or can even cause ulceration



VAD Protection & Stabilization

- Site protection (e.g., waterproof sleeve, dry garment, plastic dome/protector, mesh sleeve
 - Site protection methods are in addition to primary dressing &securement device.
- b) Joint stabilization (ONLY if absolutely necessary—restricts movement of already stiff joints)
- c) Restraint/physical immobilization device (e.g., soft device, tie or mitt used to immobilize arm or hand)





Types of blood transfusion

- Allogenic blood transfusion (someone else's blood)
 Autologous blood transfusion (own blood)
 Exchange blood transfusion





IV Access



- Transfusing rapidly and under pressure through too small an IV access can cause destruction of red blood cells. What is considered "too small"?
- Ensure that the IV access is dedicated to the transfusion. • Medications and solutions other than normal saline can cause hemolysis or clotting of the blood component
- When transfusing through a CVAD with multiple lumens, medications/solutions can be infused through other lumens without damaging the blood component/product.
- IV pumps, blood warmers, and rapid infusers must be suitable for transfusion and not damage the blood component/product.

Practice Guide

- Follow your provincial standards for blood transfusion
- REMEMBER:
- A blood transfusion is a human tissue transplant.
- Anemia tolerance is based on the assessment of signs and symptoms.
- Provide clinical information related to anemia tolerance when reporting lab values.
- Verify blood products at the patient's bedside according to facility policy and procedure.
- Transfuse one unit of RBCs at a time, then reassess the patient.
- Limit phlebotomy and blood loss from lab testing.

PRODUCT/COMPONENT CATEGORY IV ACCESS				
RED BLOOD CELLS	RAPID TRANSFUSION IN ADULTS	20 - 22 Ga		
RED BLOOD CELLS	ROUTINE TRANSFUSIONS IN ADULTS	22 – 24 Ga		
OTHER BLOOD COMPONENTS		ANY SIZE ADEQUATE		
All Blood Components/Products	Pediatrics and Adults	22-25G		
All Blood Components/Products	Adults and Pediatrics	Central Venous Access Devices (CVAD)		


Acute Reactions - Risk and Description					
Acute Transfusion Reaction	Risk of Event	Description			
Minor Allergic Reaction	1 in 100	Mild allergic reaction to an allergen in the blood component/product.			
Anaphylaxis	1 in 40,000	Potentially fatal reaction caused by an allergen that the patient has been sensitized to. STOP transfusion			
Febrile Non-Hemolytic	1 in 300	Mid usually self-limiting reaction associated with donor white blood class or cytokines in the blood component/product. Usually presents with fever and/or rigors (shaking).			

Acute Transfusion Reaction	Risk of Event	Description
Acute Hemolytic Transfusion Reaction	1 in 40,000	Potentially fatal reaction caused by blood group incompatibility. Can also be caused by chemical hemolysis (e.g. incompatible solutions) or mechanical hemolysis (e.g. improper storage). Can resu in renal failure, shock and coagulopathy.
Transfusion Related Acute Lung Injury (TRALI)	1 in 12,000	Acute hypoxemia with evidence of new bilateral lung infiltrates on X- Ray and no evidence of circulatory overload. Patients often require ventilatory support. Usually occurs within 12-4 Downs of start of transitusion and rarely after 6 hours. Usually resolves within 24-72 hours with death occurring in 5-10%. Cause and fully understood. Postulated to be related to donor or recipient antibodies acquired through pregnancy or transfusion.

Acute Reactions - Risk and Description			
Acute Transfusion Reaction	Risk of Event	Description	
Transfusion Associated Circulatory Overload (TACO)	1 in 100	Circulatory overload from excessively rapid transfusion and/or in patients at greater risk for overload (e.g. very young, elderly, impaired cardiac function). Preventative measures include slower transfusion rates and pre-emptive diuretics for patients at risk.	
Hypotensive Reaction	Very Rare	Bradykinin mediated hypotension. Characterized by profound drop in blood pressure usually seen in patients on ACE inhibitors unable to degrade bradykinin in blood component/product.	



Parenteral Nutrition

- Define terminology related to parenteral nutrition (PN) and implications for vascular access.
- Discuss potential complications of PN and associated interventions
- Identify clinical implications for peripheral PN.
- Types and composition of PN.
- Indications for PN.
- Supplies and procedures for PN administration.

What is Parenteral Nutrition?

- Provides essential nutrients and calories intravenously, when the person cannot meet these needs through oral diet or enteral feeding
- PN composed of carbohydrates, fats, protein, amino acids, minerals and vitamins
- Amount of each component is individualised, based on patient assessment
- 3 types:
 PPN: Peripheral Parenteral Nutrition
 TPN: Total Parenteral Nutrition
 - TNA: Total nutrient admixture

- Indications
- Bowel disorders such as short bowel syndrome
- Inflammatory bowel disease
- Fistulas
- Bowel Obstruction
- Malabsorption disorders (pancreatitis, cystic fibrosis)
- Motility Disorders
- Cancer

Administration

Continuous or Cyclic

- Continuous
 Infusion over a 24 hour period
 Patient is usually in a hospital setting
 May be receiving PN, TPN or TNA

- Cyclical
 8-12 hr infusions, typically overnight
 Preferred method as it allows patient more freedom during awake hours
 More closely mimic normal oral intake (period of fasting between meals)
 Decreases the risks associated with long term TPN

Complications

Most common complication is VAD infection

- Prevention:
 - Aseptic Technique
 - Change dressing as per institution protocol
 - Change IV lines every 24 hrs or at the start of every new infusion
- Line occlusion
 - Fibrin sheath
 - Intraluminal occlusion from infusate

Complications

- Long term PN may lead to Fatty Liver disease
- Cholecystitis
- Caused by lack of use of the Gut = Bile build up = inflammation
- Feelings of Hunger
 - Never actually feel full. Long term TPN without oral intake can lead to gut atrophy
- Refeeding Syndrome
 - Can occur when restarting solids